Results 201 to 210 of about 63,819 (300)
Dupilumab in Cholinergic Urticaria: An Exploratory Phase 2 Investigator‐Initiated Study
Allergy, EarlyView.
Annika Gutsche +15 more
wiley +1 more source
ABSTRACT Among bacteria that are associated with the development and/or exacerbation of allergic/atopic diseases, several have been described to produce IgE‐binding components. However, only one bacterial protein, Bac s 1, is currently listed in the official database of the World Health Organization/International Union of Immunological Societies (WHO ...
Uta Jappe +24 more
wiley +1 more source
Real-World Effectiveness, Corticosteroid-Sparing Effects, and Exploratory Immunological Correlates of Omalizumab Add-On Therapy in Hospitalized Patients with Acute Urticaria. [PDF]
Jiang T, Zhang Z, Wu L, Li J, Zhang R.
europepmc +1 more source
Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz +22 more
wiley +1 more source
Development of cold urticaria after cryotherapy during laser epilation for pilonidal disease: a case report. [PDF]
Jo S, Abrajano C, Chiu B.
europepmc +1 more source
In this Phase 2a trial, severely peanut‐allergic participants were randomized to abatacept versus placebo with peanut oral immunotherapy (OIT) for 24 weeks, followed by 12 weeks of OIT alone. No significant difference was observed for the primary efficacy outcome (the relative change from baseline in peanut‐specific/total IgE ratio at 24 weeks), but ...
Marie‐Lee Simard +12 more
wiley +1 more source
Wheat-Dependent Exercise-Induced Anaphylaxis Mimicking Acute Asthma in an Adolescent: A Case Report. [PDF]
Zhao X +6 more
europepmc +1 more source

